Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pediatric Endocrinology and Metabolism"
DOI: 10.1515/jpem-2019-0581
Abstract: Abstract Background Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand, which strongly suppresses osteoclasts. Cherubism is a rare autosomal dominant disorder characterized by symmetrical swelling of the jaws, in which the… read more here.
Keywords: efficacy safety; cherubism; treatment; denosumab ... See more keywords